Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIQ-AI Regulatory News (IQAI)

  • There is currently no data for IQAI

Result of AGM

11 Jun 2014 11:42

RNS Number : 3714J
Flying Brands Limited
11 June 2014
 



11 June 2014

 

FLYING BRANDS LIMITED

 

RESULT OF ANNUAL GENERAL MEETING

 

The Board of Flying Brands Limited (the "Company") is pleased to announce that at the Company's Annual General Meeting held on Wednesday 11 June 2014 (the "AGM") the resolutions as set out in the Notice of AGM were duly passed on a show of hands, save that resolution number 2 set out in the Notice of AGM was withdrawn as having been originally included in error.

 

The following levels of proxy appointments were received by the Company prior to the AGM:

 

Resolution

For

Against

Chairman's discretion (Note i)

Votes withheld

Number of shares

% of total

Number of shares

% of total

Number of shares

% of total

1. To receive and adopt the report and accounts

 

13,900,780

99.76

1.930

0.01

32,644

0.23

1,125,000

2. To approve the Remuneration Committee Report

 

14.974,987

99.44

52,521

0.35

31,704

0.21

1,142

3. To re-appoint Stephen Cook as a director

 

14,982,987

99.48

44,650

0.30

32,644

0.22

233

4. To re-appoint Deloitte LLP as auditor and to authorise the directors to determine their remuneration

 

15,022,759

99.75

4,808

0.03

32,554

0.22

233

5. Special Resolution - To authorise the directors to make market purchases of ordinary shares

 

15,018,463

99.73

6,065

0.04

35,010

0.23

816

6. Special Resolution - To authorise the directors to allot ordinary shares without rights of pre-emption

12,314,128

81.77

2,711,167

18.00

34,010

0.23

1,049

 

Notes:

(i) Proxy appointments which gave discretion to the Chairman have been cast in favour of each resolution.

 

(ii) Issued share capital at 11 June 2014: 28,073,735 ordinary shares. Proxy appointments were received from shareholders holding the number of shares shown below, in each case representing the percentage of the issued share capital shown alongside:

 

Resolution 1

15,060,354

53.65%

Resolution 2

15,060,354

53.65%

Resolution 3

15,060,354

53.65%

Resolution 4

15,060,354

53.65%

Resolution 5

15,060,354

53.65%

Resolution 6

15,060,354

53.65%

 

 

(iii) A "Vote Withheld" is not counted towards the votes cast "For" or "Against" the resolutions.

 

 

 

For further information, please contact:

 

Smithfield Consultants 020 7360 4900

John Kiely

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGFBMMTMBJBBRI
Date   Source Headline
27th May 20257:00 amRNSChange of Name
22nd May 20252:23 pmRNSResult of AGM
2nd May 20257:29 amRNSApplication: FDA Breakthrough Therapy Designation
29th Apr 202510:49 amRNSNotice of AGM
25th Apr 20251:46 pmRNSPublication of Annual Report
11th Apr 20253:32 pmRNSPromising Preliminary Results of Phase 1 Study
18th Mar 202510:38 amRNSPlacing to raise £250,000
3rd Feb 20257:00 amRNSIB Expands Distribution with Blackford
22nd Jan 20257:00 amRNSOperations Update
10th Jan 20257:49 amRNSIB and Prism Secure First Installation
20th Nov 20247:00 amRNSImaging Biometrics Expands Distribution
19th Nov 202411:27 amRNSBoard Changes
5th Nov 20247:00 amRNSNew Patent Application and Trading Update
15th Oct 202410:28 amRNSHolding(s) in Company
14th Oct 202412:08 pmRNSHolding(s) in Company
14th Oct 202412:05 pmRNSPDMR dealing and TR1 announcement
11th Oct 202410:42 amRNSAcquisition of Interest by Braveheart
25th Jun 20249:59 amRNSIB Opens Expanded Access Program
14th Jun 20248:38 amRNSClinical Trial Updates
29th May 20243:08 pmRNSResult of AGM
23rd May 20247:00 amRNSMajor East Coast Health System Chooses IB Nimble
20th May 20247:10 amRNSSecond FDA Rare Pediatric Disease Designation
17th May 20247:00 amRNSIB Software Enhances Clinical Decision-Making
10th May 20248:15 amRNSRare Pediatric Disease Designation Granted to GaM
2nd May 202412:47 pmRNSIB Announces Expanded Access Program for GaM
29th Apr 20243:26 pmRNSPublication of Annual Report
5th Mar 20247:00 amRNSGrant of Options
1st Mar 20248:22 amRNSHolding(s) in Company
1st Mar 20248:20 amRNSHolding(s) in Company
26th Feb 20247:00 amRNSResult of Broker Option and Total Voting Rights
22nd Feb 20247:00 amRNSPlacing and Broker Option
9th Feb 202412:49 pmRNSFDA Application Update
2nd Feb 20248:39 amRNSIB awarded a $100,000 grant
22nd Jan 202410:05 amRNSHolding(s) in Company
15th Jan 20247:01 amRNSDirector Dealings and Conversion of CLNs
15th Jan 20247:00 amRNSHolding(s) in Company
10th Jan 20247:00 amRNSIB Launching an Expanded Access Program for GaM
19th Dec 20232:29 pmRNSImaging Biometrics granted FDA “Fast-Track”
5th Dec 202310:58 amRNSIQ-AI Announces Positive Interim Phase 1 Results
20th Nov 20231:42 pmRNSHolding(s) in Company
9th Nov 202311:38 amRNSDirector Dealing and Conversion of CLNs
8th Nov 202310:59 amRNSApplication for Pediatric Rare Disease Designation
6th Nov 20231:02 pmRNSHolding(s) in Company
18th Oct 20232:29 pmRNSUpdate Regarding Imaging Biometrics LLC
13th Oct 20238:55 amRNSIB Letter to Shareholders
9th Oct 20237:00 amRNSOrphan Drug Status to GaM and Total Voting Rights
3rd Oct 202311:30 amRNSHolding(s) in Company
19th Sep 20232:32 pmRNSIQ-AI shares cease trading on the OTCQB
8th Sep 20237:00 amRNSReduced Gadolinium Approach Validated'
18th Aug 202312:06 pmRNSUpdate on Collaboration Agreement with Mayo Clinic

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.